OTC:CC - Ocumetics Continues to Meet Significant Development Milestones; Lens Design Optimized for Upcoming First in Human Study
(TheNewswire)
Calgary, Alberta – September 18, 2023. Ocumetics Technology Corp.(“ Ocumetics ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO),a pioneer in in the field of ophthalmicinnovation, proudly confirms a remarkable achievement in theoptimization of its vision correction technology - the OcumeticsAccommodating Lens. Through rigorous research and development effortsover the past two years, Ocumetics has modified its lens design fivetimes, ultimately arriving at its groundbreaking final lensconfiguration version 10.5. Lens version 10.5 has been tested in vitroand in an animal model, and will be used in Ocumetics’ upcominghuman clinical trials.
This achievement is a testament to Ocumetics'persistence and unwavering commitment to delivering the most advancedand efficient vision correction solution possible. The optimizationprocess has been conducted with a meticulous focus on quality andperformance, ensuring that the upcoming first-in-human study,anticipated to commence in Q1 2024 in the Dominican Republic, willbenefit from the most advanced technology available.
Dr. Garth Webb, Founder and Chief Scientific Officer ofOcumetics, emphasized the importance of this achievement, stating,"Entering the first-in-human study with an optimized lens designis paramount to our mission. We have relentlessly pursued excellenceto ensure that our technology offers the best possible visioncorrection experience for patients."
Dean Burns, President and CEO of Ocumetics, highlightedthe company's innovative culture, saying, "Our success inoptimizing the lens design underscores our dedication to understandingthe needs of patients and listening to our valued investigators andadvisors. This iterative process reflects our commitment todelivering on our promise of enhanced vision."
Dean Burns adds, “Ocumetics remains at the forefrontof vision correction technology research and is dedicated totransforming the lives of individuals worldwide. The achievement ofa final configuration of the Ocumetics Accommodating Lens version 10.5marks a significant milestone in the company's relentless pursuit ofexcellence, and was made possible by the ability of our extraordinaryteam to quickly develop exceptional solutions for all product designchallenges encountered.”
About Ocumetics
Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO),headquartered in Calgary, Alberta, Canada, is an innovator in the field of ophthalmic technology, dedicated todeveloping and commercializing advanced vision correction solutionsthat enhance the quality of life for individuals worldwide.
Ocumetics is in the preclinical study stage of agame-changing technology for the ophthalmic industry. In its pursuitof a next generation interocular lens solution, Ocumetics hasdeveloped the Ocumetics Accommodating Lens, an expandable intraocularlens that fits within the natural lenscompartment of the eye potentially to eliminate the need forcorrective lenses. It is designed to allow the eye’s naturalmuscle activity to seamlessly shift focus from distance tointermediate to near.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dean Burns Dayton Marks
President and CEO Director
(817) 874-7564 (778)347-2500
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
Copyright (c) 2023 TheNewswire - All rights reserved.